Read as much as you want on, anywhere and anytime, for just 99¢.

Mass. mover

Alnylam Pharmaceuticals settles legal battle

Alnylam and Tekmira entered a settlement.

Alnylam and Tekmira entered a settlement.

Continue reading below

Alnylam Pharmaceuticals Inc., a Cambridge company looking to develop therapeutics based on RNA interference, said it has restructured its relationship with Tekmira Pharmaceuticals with a new licensing agreement. It also said the companies have resolved all litigation between them. Tekmira will receive $65 million, and is eligible to receive $10 million in near-term milestone payments. The litigation involved intellectual property rights of lipid nanoparticle technology, Tekmira said.

Loading comments...
Subscriber Log In

You have reached the limit of 5 free articles in a month

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of
Marketing image of